stride study semaglutide 🔴The trial! 👟⤵️ 🔹The STRIDE trial demonstrated that significantly improves function, symptoms, and health-related QoL in patients with symptomatic #cvPAD and T2DM STRIDE: Semaglutide Improves Functional Outcomes

And so, that would be people who have a BMI of 30 or more, or people with a BMI of 27 with one or more weight-related health conditions

Semaglutide should not be used if you or your family has a history of certain thyroid tumors or Multiple Endocrine Neoplasia type 2 syndrome

What causes them

Conflict of Interest Statement The authors are employees of nference, inc., which conducts research collaborations with various biopharmaceutical companies, including Eli Lilly and Company and Novo Nordisk A/S, whose GLP-1 receptor agonist products (tirzepatide and semaglutide) are included in this study

But again, we'll have to wait to see what UK regulators say before we know for certain

Patients taking GLP1/GIP medication may also be advised to monitor their blood pressure and lipid levels, as these can be affected by diabetes and may be further impacted by the GLP1/GIP medication